Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of tislelizumab plus platinum-doublet chemotherapy in resectable non-small cell lung cancer
CTR20200821Phase 3Active
- Sponsor
- BeOne Medicines
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by BeOne Medicines. Started Jun 2020; status: active.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200821.